BG lab at Queen’s University, Kingston, Canada (PI: Bishal Gyawali) is a world-renowned research center working at the intersection of global oncology and cancer policy, conducting meaningful research, policy, and advocacy work grounded in the philosophy of cancer groundshot.
BG Lab’s main focus includes global oncology and cancer equity, cost of cancer treatments including financial toxicity, regulatory policy including drug approval and reimbursement processes, mentorship, and inspiring the next generation of oncologists.
Projects
Our team is studying elements of clinical trial design and reporting including crossover, the use of surrogate endpoints, and quality of life reporting. We also study HTA criteria for cancer drug reimbursement across several countries. Our work is synergistic with the Common Sense Oncology movement, of which Dr. Gyawali is a co-founder.
We partner with several international collaborators to improve cancer care outcomes globally, with a focus in Nepal and India.
Our team has also published several cancer-site specific clinical research with an aim to improve outcomes for people living with cancer. We have published studies on treatments of head and neck cancer, prostate cancer, breast cancer, chemotherapy induced nausea and vomiting, febrile neutropenia.
Common Sense Oncology
Along with his mentor Dr. Chris Booth, Dr. Gyawali is a co-leader of Common Sense Oncology (CSO).
CSO is a growing movement of physicians, patients, advocates, researchers, and stakeholders globally to ensure that cancer research and policy is aligned with the goal of improving outcomes that matter to our patients.
Please visit the CSO website for more information on this movement.
Dr. Bishal Gyawali 